COVID-19 Clinical Status Associated With Outcome Severity: An Unsupervised Machine Learning Approach

May 14, 2023 updated by: Prof. Triantafyllos Didangelos, Aristotle University Of Thessaloniki

Does Corona Virus Disease (COVID)-19 Clinical Status Associates With Outcome Severity?An Unsupervised Machine Learning Approach for Knowledge Extraction

Since the beginning of the COVID-19 pandemic, 195 million people have been infected and 4.2 million have died from the disease or its side-effects. Physicians, healthcare scientists and medical staff continuously try to deal with overloaded hospital admissions, while in parallel, they try to identify meaningful correlations between the severity of infected patients with their symptoms, comorbidities and biomarkers. Artificial Intelligence (AI) and Machine Learning (ML) have been used recently in many areas related to COVID-19 healthcare. The main goal is to manage effectively the wide variety of issues related to COVID-19 and its consequences. The existing applications of ML to COVID-19 healthcare are based on supervised classification which require a labeled training dataset, serving as reference point for learning, as well as predefined classes. However, the existing knowledge about COVID-19 and its consequences is still not solid and the points of common agreement among different scientific communities are still unclear.

Therefore, this study aimed to follow an unsupervised clustering approach, where prior knowledge is not required (tabula rasa).

More specifically, 268 hospitalized patients at the First Propaedeutic Department of Internal Medicine of AHEPA University Hospital of Thessaloniki were assessed in terms of 40 clinical variables (numerical and categorical), leading to a high-dimensionality dataset. Dimensionality reduction was performed by applying Principal Component Analysis (PCA) on the numerical part of the dataset and Multiple Correspondence Analysis (MCA) on the categorical part of the dataset. Then, the Bayesian Information Criterion(BIC) was applied to Gaussian Mixture Models (GMM) in order to identify the optimal number of clusters, under which, the best grouping of patients occurs.

The proposed methodology identified 4 clusters of patients with similar clinical characteristics. The analysis revealed a cluster of asymptomatic patients that resulted in death at a rate of 23.8%.

This striking result forces us to reconsider the relationship between the severity of COVID-19 clinical symptoms and patient's mortality.

Study Overview

Status

Completed

Conditions

Detailed Description

An algorithmic pipeline based on unsupervised machine learning algorithms, which aims to operate in tandem with physicians and provide additional knowledge for the proper categorization of COVID-19 infected patients based on their severity, is proposed in this study. Data from patients hospitalized in our clinic are collected and stored in separate Microsoft Excel files (.xlsx), which are loaded into memory. A script is concatenating them all into a single dataframe where they are checked for NaN (Not a Number) values. Because of the nature of the data, patients with missing information are discarded entirely from the dataset, since information inference would be a biased practice for the particular application. Next, we apply data normalization by scaling all numerical variables between the (0,1) range, so that the range of all numerical variables is the same, and any bias towards certain variables is avoided .A thorough and detailed data collection process was designed in order to collect information for the patients, without disturbing the clinical treatment, or upsetting them in the process.

Study Type

Observational

Enrollment (Actual)

268

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Thessaloníki, Greece, 54621
        • University General Hospital of Thessaloniki AHEPA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients that came into emergency department and diagnosed with COVID-19 infection

Description

Inclusion Criteria:

  • patients that came into emergency department and diagnosed with COVID-19 infection

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group
Hospitalized Patients with Corona virus disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cluster of patients depending on severity of infection
Time Frame: 1 year
Algorithm produced with artificial intelligence and machine learning approach to classify patients according their status of COVID-19 infection
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2019

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

November 12, 2021

First Submitted That Met QC Criteria

November 12, 2021

First Posted (Actual)

November 15, 2021

Study Record Updates

Last Update Posted (Actual)

May 16, 2023

Last Update Submitted That Met QC Criteria

May 14, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe